← All Signals

🏥 FDA: Wizcure Pharmaa Private Limited — Class II

healthcareactionableSource: FDA
97%Confidence
0Views
FDASource
2026-03-16Date

Summary

The final Wizcure recall for another advanced dry eye formula solidifies a major quality crisis at the manufacturer, affecting multiple distributors and product types. This creates a market opportunity for competitors in the dry eye treatment segment.

Actionable: Capitalize on the market gap by promoting alternative, reliably manufactured dry eye relief products.

AI Confidence: 97%

Data Points

firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productVista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula, 10 ml (1/3 fl.oz.), Wizcure Pharmaa PVT. LTD., H-8

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now